[1] |
Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS)[J]. Human Reprod, 2004, 19(1): 41-47.
|
[2] |
Li R, Zhang Q, Yang D, et al. Prevalence of polycystic ovary syndrome in women in China: a large community-based study[J]. Hum Reprod, 2013, 28(9): 2562-2569.
|
[3] |
Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. Consensus on women′s health aspects of polycystic ovary syndrome (PCOS)[J]. Hum Reprod, 2012, 27(1): 14-24.
|
[4] |
Murri M, Luque-Ramírez M, Insenser M, et al. Circulating markers of oxidative stress and polycystic ovary syndrome (PCOS): a systematic review and Meta-analysis[J]. Hum Reprod Update, 2013, 19(3): 268-288.
|
[5] |
Zhang J, Fan P, Liu H, et al. Apolipoprotein A-I and B levels, dyslipidemia and metabolic syndrome in south-west Chinese women with PCOS[J]. Hum Reprod, 2012, 27(8): 2484-2493.
|
[6] |
Lim SS, Davies MJ, Norman RJ, et al. Overweight, obesity and central obesity in women with polycystic ovary syndrome: a systematic review and Meta-analysis[J]. Hum Reprod Update, 2012, 18(6): 618-637.
|
[7] |
de Groot PC, Dekkers OM, Romijn JA, et al. PCOS, coronary heart disease, stroke and the influence of obesity: a systematic review and Meta-analysis[J]. Hum Reprod Update, 2011, 17(4): 495-500.
|
[8] |
McAllister JM, Legro RS, Modi BP, et al. Functional genomics of PCOS: from GWAS to molecular mechanisms[J]. Trends Endocrinol Metab, 2015,26(3):118-124.
|
[9] |
Shi Y, Zhao H, Shi Y, et al. Genome-wide association study identifies eight new risk loci for polycystic ovary syndrome [J]. Nat Genet, 2012, 44(9): 1020-1025.
|
[10] |
Pisoschi AM, Pop A. The role of antioxidants in the chemistry of oxidative stress: a review[J]. Eur J Med Chem, 2015, 97: 55-74.
|
[11] |
Zhang R, Liu H, Bai H, et al. Oxidative stress status in Chinese women with different clinical phenotypes of polycystic ovary syndrome[J]. Clin Endocrinol (Oxf), 2017, 86(1): 88-96.
|
[12] |
Zuo T, Zhu M, Xu W. Roles of oxidative stress in polycystic ovary syndrome and cancers[J]. Oxid Med Cell Longev, 2016, 2016: 8589318.
|
[13] |
Kajihara T, Tochigi H, Prechapanich J, et al. Androgen signaling in decidualizing human endometrial stromal cells enhances resistance to oxidative stress[J]. Fertil Steril, 2012, 97(1): 185-191.
|
[14] |
González F, Nair KS, Daniels JK, et al. Hyperandrogenism sensitizes leukocytes to hyperglycemia to promote oxidative stress in lean reproductive-age women[J]. J Clin Endocrinol Metab, 2012, 97(8): 2836-2843.
|
[15] |
Gonzalez F, Sia CL, Shepard MK, et al. Hyperglycemia-induced oxidative stress is independent of excess abdominal adiposity in normal-weight women with polycystic ovary syndrome[J]. Hum Reprod, 2012, 27(12): 3560-3568.
|
[16] |
Agarwal A, Aponte-Mellado A, Premkumar BJ, et al. The effects of oxidative stress on female reproduction: a review[J]. Reprod Biol Endocrinol, 2012, 10: 49.
|
[17] |
Geybels MS, van den Brandt PA, van Schooten FJ, et al. Oxidative stress-related genetic variants, pro- and antioxidant intake and status, and advanced prostate cancer risk[J]. Cancer Epidemiol Biomarkers Prev, 2015, 24(1): 178-186.
|
[18] |
Erel O. A new automated colorimetric method for measuring total oxidant status[J]. Clin Biochem, 2005, 38(12): 1103-1111.
|
[19] |
Zhang Y, Liu H, He J, et al. Lactonase activity and status of paraoxonase 1 in Chinese women with polycystic ovarian syndrome[J]. Eur J Endocrinol, 2015, 172(4): 391-402.
|
[20] |
Zhang J, Zhang Y, Liu H, et al. Antioxidant properties of high-density lipoproteins are impaired in women with polycystic ovary syndrome[J]. Fertil Steril, 2015, 103(5): 1346-1354.
|
[21] |
Fan P, Liu H, Wang Y, et al. Apolipoprotein E-containing HDL-associated platelet-activating factor acetylhydrolase activities and malondialdehyde concentrations in patients with PCOS[J]. Reprod Biomed Online, 2012, 24(2): 197-205.
|
[22] |
Savic-Radojevic A, Bozic Antic I, Coric V, et al. Effect of hyperglycemia and hyperinsulinemia on glutathione peroxidase activity in non-obese women with polycystic ovary syndrome[J]. Hormones (Athens), 2015, 14(1): 101-108.
|
[23] |
Nisenblat V, Norman RJ. Androgens and polycystic ovary syndrome[J]. Curr Opin Endocrinol Diabetes Obes, 2009, 16(3): 224-231.
|
[24] |
Moore AM, Prescott M, Marshall CJ, et al. Enhancement of a robust arcuate GABAergic input to gonadotropin-releasing hormone neurons in a model of polycystic ovarian syndrome[J]. Proc Natl Acad Sci U S A, 2015,112(2): 596-601.
|
[25] |
Hurliman A, Keller Brown J, Maille N, et al. Hyperandrogenism and insulin resistance, not changes in body weight, mediate the development of endothelial dysfunction in a female rat model of polycystic ovary syndrome (PCOS)[J]. Endocrinology, 2015, 156(11): 4071-4080.
|
[26] |
Burt Solorzano CM, Beller JP, Abshire MY, et al. Neuroendocrine dysfunction in polycystic ovary syndrome[J]. Steroids, 2012, 77(4): 332-337.
|
[27] |
Newell-Fugate AE, Taibl JN, Alloosh M, et al. Effects of obesity and metabolic syndrome on steroidogenesis and folliculogenesis in the female Ossabaw mini-pig[J]. PLoS One, 2015, 10(6): e0128749.
|
[28] |
Unfer V, Carlomagno G, Dante G, et al. Effects of myo-inositol in women with PCOS: a systematic review of randomized controlled trials[J]. Gynecol Endocrinol, 2012, 28(7): 509-515.
|
[29] |
Bremer AA, Miller WL. The serine phosphorylation hypothesis of polycystic ovary syndrome: a unifying mechanism for hyperandrogenemia and insulin resistance[J]. Fertil Steril, 2008, 89(5): 1039-1048.
|
[30] |
Duleba AJ, Spaczynski RZ, Olive DL. Insulin and insulin-like growth factor Ⅰ stimulate the proliferation of human ovarian theca-interstitial cells[J]. Fertil Steril, 1998, 69(2): 335-340.
|
[31] |
Ibáñez L, Potau N, Zampolli M, et al. Hyperinsulinemia and decreased insulin-like growth factor-binding protein-1 are common features in prepubertal and pubertal girls with a history of premature pubarche[J]. J Clin Endocrinol Metab, 1997, 82(7): 2283-2288.
|
[32] |
Nestler JE, Powers LP, Matt DW, et al. A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome[J]. J Clin Endocrinol Metab, 1991, 72(1): 83-89.
|
[33] |
Kodaman PH, Duleba AJ. Statins in the treatment of polycystic ovary syndrome[J]. Semin Reprod Med, 2008,26(1):127-138.
|
[34] |
Nikolić M, Macut D, Djordjevic A, et al. Possible involvement of glucocorticoids in 5alpha-dihydrotestosterone-induced PCOS-like metabolic disturbances in the rat visceral adipose tissue[J]. Mol Cell Endocrinol, 2015, 399: 22-31.
|
[35] |
González F, Nair KS, Daniels JK, et al. Hyperandrogenism sensitizes mononuclear cells to promote glucose-induced inflammation in lean reproductive-age women[J]. Am J Physiol Endocrinol Metab, 2012, 302(3): E297-E306.
|
[36] |
Zhao Y, Zhang C, Huang Y, et al. Up-regulated expression of WNT5a increases inflammation and oxidative stress via PI3K/AKT/NF-kappaB signaling in the granulosa cells of PCOS patients[J]. J Clin Endocrinol Metab, 2015, 100(1): 201-211.
|
[37] |
Zhao H, Zhao Y, Li T, et al. Metabolism alteration in follicular niche: the nexus among intermediary metabolism, mitochondrial function, and classic polycystic ovary syndrome[J]. Free Radic Biol Med, 2015, 86: 295-307.
|
[38] |
Fernández-Sánchez A, Madrigal-Santillán E, Bautista M, et al. Inflammation, oxidative stress, and obesity[J]. Int J Mol Sci, 2011, 12(5): 3117-3132.
|
[39] |
苏椿淋,黄海艳,沈宗奇,等. 睾酮对3T3-L1脂肪细胞炎症因子生成的影响及其机制研究[J]. 中华医学杂志,2009, 89(21): 1493-1497.
|
[40] |
Brites F, Martin M, Guillas I, et al. Antioxidative activity of high-density lipoprotein (HDL): mechanistic insights into potential clinical benefit[J]. BBA Clin, 2017, 8: 66-77.
|
[41] |
Mackness B, Mackness M. The antioxidant properties of high-density lipoproteins in atherosclerosis[J]. Panminerva Med, 2012, 54(2): 83-90.
|
[42] |
Pandey V, Singh A, Singh A, et al. Role of oxidative stress and low-grade inflammation in letrozole-induced polycystic ovary syndrome in the rat[J]. Reprod Biol, 2016, 16(1): 70-77.
|
[43] |
Evans JL, Maddux BA, Goldfine ID. The molecular basis for oxidative stress-induced insulin resistance[J]. Antioxid Redox Signal, 2005, 7(7-8): 1040-1052.
|
[44] |
Legro RS, Arslanian SA, Ehrmann DA, et al. Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline[J]. J Clin Endocrinol Metab, 2013, 98(12): 4565-4592.
|
[45] |
Escobar-Morreale HF, Carmina E, Dewailly D, et al. Epidemiology, diagnosis and management of hirsutism: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome Society[J]. Hum Reprod Update, 2012, 18(2): 146-170.
|
[46] |
Köse SA, NazIroĝlu M. N-acetyl cysteine reduces oxidative toxicity, apoptosis, and calcium entry through TRPV1 channels in the neutrophils of patients with polycystic ovary syndrome[J]. Free Radic Res, 2015, 49(3): 338-346.
|
[47] |
Macut D, Bjekić-Macut J, Savić-Radojević A. Dyslipidemia and oxidative stress in PCOS[J]. Front Horm Res, 2013, 40: 51-63.
|
[48] |
Cheraghi E, Mehranjani MS, Shariatzadeh MA, et al. N-Acetylcysteine improves oocyte and embryo quality in polycystic ovary syndrome patients undergoing intracytoplasmic sperm injection: an alternative to metformin[J]. Reprod Fertil Dev, 2016,28(6):723-731.
|
[49] |
Maged AM, Elsawah H, Abdelhafez A, et al. The adjuvant effect of metformin and N-acetylcysteine to clomiphene citrate in induction of ovulation in patients with Polycystic Ovary Syndrome[J]. Gynecol Endocrinol, 2015, 31(8): 635-638.
|
[50] |
Spritzer PM, Lecke SB, Fabris VC, et al. Blood trace element concentrations in polycystic ovary syndrome: systematic review and Meta-analysis[J]. Biol Trace Elem Res, 2017, 175(2): 254-262.
|
[51] |
Razavi M, Jamilian M, Kashan ZF, et al. Selenium supplementation and the effects on reproductive outcomes, biomarkers of inflammation, and oxidative stress in women with polycystic ovary syndrome[J]. Horm Metab Res, 2016,48(3): 185-190.
|
[52] |
Mohammad Hosseinzadeh F, Hosseinzadeh-Attar MJ, Yekaninejad MS, et al. Effects of selenium supplementation on glucose homeostasis and free androgen index in women with polycystic ovary syndrome: a randomized, double blinded, placebo controlled clinical trial[J]. J Trace Elem Med Biol, 2016, 34: 56-61.
|
[53] |
Bahmani F, Karamali M, Shakeri H, et al. The effects of folate supplementation on inflammatory factors and biomarkers of oxidative stress in overweight and obese women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled clinical trial[J]. Clin Endocrinol (Oxf), 2014, 81(4): 582-587.
|
[54] |
Goodman NF, Cobin RH, Futterweit W, et al. American Association of Clinical Endocrinologists, American College of Endocrinology, and androgen excess and PCOS society disease state clinical review: guide to the best practices in the evaluation and treatment of polycystic ovary syndrome - part 2[J]. Endocr Pract, 2015, 21(12): 1415-1426.
|
[55] |
Puurunen J, Piltonen T, Puukka K, et al. Statin therapy worsens insulin sensitivity in women with polycystic ovary syndrome (PCOS): a prospective, randomized, double-blind, placebo-controlled study[J]. J Clin Endocrinol Metab, 2013, 98(12): 4798-4807.
|
[56] |
Kwintkiewicz J, Foyouzi N, Piotrowski P, et al. Mevastatin inhibits proliferation of rat ovarian theca-interstitial cells by blocking the mitogen-activated protein kinase pathway[J]. Fertil Steril, 2006, 86(4 Suppl): 1053-1058.
|